Switching double-blind opicapone, entacapone or placebo to open-label opicapone: Efficacy results of the 1-year extension of study BIPARK I
Objective: Evaluate the efficacy of opicapone (OPC) in Parkinson's disease (PD) patients with motor fluctuations enrolled in the 1-year extension of study BIPARK I. Background:…Monitoring dyskinesia severity using wearable sensor data
Objective: Herein we present the results of ongoing work focused on estimating limb-specific dyskinesia in patients with PD using wearable sensor data collected in the…Outpatient management of Parkinson’s disease: A review of medication changes made to address both motor and non-motor symptoms
Objective: To identify reasons for medication changes at outpatient movement disorder clinics and determine outcome of these changes at next clinic visit. Background: Parkinson's disease…Automated assessment of advanced motor Parkinson’s disease; a pilot study of the Parkinson’s KinetiGraph as an objective tool for measurement of motor fluctuations
Objective: To evaluate the utility of the Parkinson's KinetiGraph (PKG) as a tool in advanced Parkinson's disease (PD) to determine need for treatment change by…Safety of opicapone in fluctuating Parkinson’s disease patients: Results of the 1-year extension of study BIPARK I
Objective: Evaluate the safety of opicapone (OPC) in Parkinson's disease patients with motor fluctuations enrolled in the 1-year extension of study BIPARK I. Background: OPC,…Differences between responders and non-responders of Istradefylline for the wearing off in Parkinson’s disease
Objective: Istradefylline is a selective antagonist of adenosine A2A receptor and was approved first in Japan for Parkinson's disease (PD) patients with by symptoms of…Opicapone in fluctuating Parkinson’s disease patients: OFF- and ON-time responder post-hoc analyses of pooled phase III studies
Objective: Evaluate the proportion of patients with Parkinson's disease and motor fluctuations responding to opicapone (OPC) or placebo treatment over a 14-15 week treatment period.…Long-duration response to levodopa in Parkinson’s disease is independent of disease duration: A prospective study on de novo patients in Ghana
Objective: To prospectively investigate the response to acute levodopa challenge in patients with advanced Parkinson's disease (PD) never treated before. Background: Pathophysiological mechanisms underlying motor…Onset and stabilization of opicapone treatment effects in fluctuating Parkinson’s disease patients: Exploratory by-week efficacy analysis of pooled phase III studies
Objective: Evaluate the onset and stability of the therapeutic effect of opicapone (OPC) compared to placebo in patients with Parkinson's disease and motor fluctuations over…Risk factors of wearing-off phenomenon in Parkinson’s disease in Japan
Objective: Parkinson's disease (PD) is one of common progressive neurodegenerative disorder involving nigrostriatal dopaminergic neurons. The aim of this study was to investigate risk factors…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.